Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid i and attenuates its nephrotoxicity

Toxicological Sciences

Volumn 122, Issue 2, 2011, Pages 288-296

  Chen, Min ^a   Gong, Likun ^a   Qi, Xinming ^a   Xing, Guozhen ^a   Luan, Yang ^a   Wu, Yuanfeng ^a   Xiao, Ying ^a   Yao, Jun ^a   Li, Yan ^a   Xue, Xiang ^a   Pan, Guoyu ^a   Ren, Jin ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Aristolactam I; Aristolochic acid nephropathy; Dicoumarol; Nitroreduction; NQO1

Indexed keywords

8 HYDROXY ARISTOLOCHIC ACID I; ARISTOLOCHIC ACID; ARISTOLOCHIC ACID I; ARISTOLOLACTAM; ARISTOLOLACTAM I; DICOUMAROL; NAD(P)H:QUINONE OXIDOREDUCTASE 1; PHENINDIONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; KIDNEY TUBULE CELL; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PLASMA CLEARANCE; PROTEIN EXPRESSION; REDUCTION; RENAL PROTECTION; SURVIVAL RATE;

ANIMALS; ARISTOLOCHIC ACIDS; DICUMAROL; ENZYME INHIBITORS; EPITHELIAL CELLS; GENE EXPRESSION; KIDNEY; KIDNEY DISEASES; MALE; MICE; MICE, INBRED C57BL; NAD(P)H DEHYDROGENASE (QUINONE); PHENINDIONE; SURVIVAL RATE;

MUS;

EID: 80051678011     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr138     Document Type: Article

References (40)

1. Benson, A. M., Hunkeler, M. J., and Talalay, P. (1980). Increase of NAD(P)H:quinone reductase by dietary antioxidants: possible role in protection against carcinogenesis and toxicity. Proc. Natl. Acad. Sci. U.S.A. 77, 5216-5220.
2. Burke, M. D., Thompson, S., Elcombe, C. R., Halpert, J., Haaparanta, T., and Mayer, R. T. (1985). Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochem. Pharmacol. 34, 3337-3345.
3. Chan, W., Cui, L., Xu, G., and Cai, Z. (2006). Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 20, 1755-1760.
4. Chan, W., Luo, H. B., Zheng, Y., Cheng, Y. K., and Cai, Z. (2007). Investigation of the metabolism and reductive activation of carcinogenic aristolochic acids in rats. Drug Metab. Dispos. 35, 866-874.
5. Chen, S., Wu, K., Zhang, D., Sherman, M., Knox, R., and Yang, C. S. (1999). Molecular characterization of binding of substrates and inhibitors to DT-diaphorase: combined approach involving site-directed mutagenesis, inhibitor-binding analysis, and computer modeling. Mol. Pharmacol. 56, 272-278.
6. Cosyns, J. P., Jadoul, M., Squifflet, J. P., De Plaen, J. F., Ferluga, D., and van Ypersele de Strihou, C. (1994). Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int. 45, 1680-1688.
7. Debelle, F. D., Vanherweghem, J. L., and Nortier, J. L. (2008). Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 74, 158-169.
8. Depierreux, M., Van Damme, B., Vanden Houte, K., and Vanherweghem, J. L. (1994). Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am. J. Kidney Dis. 24, 172-180.
9. Dong, H., Suzuki, N., Torres, M. C., Bonala, R. R., Johnson, F., Grollman, A. P., and Shibutani, S. (2006). Quantitative determination of aristolochic acid-derived DNA adducts in rats using 32P-postlabeling/polyacrylamide gel electrophoresis analysis. Drug Metab. Dispos. 34, 1122-1127.
10. Grollman, A. P., Shibutani, S., Moriya, M., Miller, F., Wu, L., Moll, U., Suzuki, N., Fernandes, A., Rosenquist, T., Medverec, Z., et al. (2007). Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl. Acad. Sci. U.S.A. 104, 12129-12134.
11. Hosoda, S., Nakamura, W., and Hayashi, K. (1974). Properties and reaction mechanism of DT diaphorase from rat liver. J. Biol. Chem. 249, 6416-6423.
12. Krumbiegel, G., Hallensleben, J., Mennicke, W. H., Rittmann, N., and Roth, H. J. (1987). Studies on the metabolism of aristolochic acids I and II. Xenobiotica 17, 981-991.
13. Kumar, V., Poonam, D., Prasad, A. K., and Parmar, V. S. (2003). Naturally occurring aristolactams, aristolochic acids and dioxoaporphines and their biological activities. Nat. Prod. Rep. 20, 565-583.
14. Levova, K., Moserova, M., Kotrbova, V., Sulc, M., Henderson, C. J., Wolf, C. R., Phillips, D. H., Frei, E., Schmeiser, H. H., Mares, J., et al. (2011). Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH: cytochrome P450 reductase null (HRN) mouse model. Toxicol. Sci. 121, 43-56.
15. Nioi, P., and Hayes, J. D. (2004). Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat. Res. 555, 149-171.
16. Pfau, W., Schmeiser, H. H., and Wiessler, M. (1990a). Aritolochic acid binds covalently to the exo-cyclic amino group of purine nucleotides in DNA. Carcinogenesis 11, 313-319.
17. Pfau, W., Schmeiser, H. H., and Wiessler, M. (1990b). 32P-postlabelling analysis of the DNA adducts formed by aristolochic acid I and II. Carcinogenesis 11, 1627-1633.
18. Radjendirane, V., Joseph, P., Lee, Y. H., Kimura, S., Klein-Szanto, A. J., Gonzalez, F. J., and Jaiswal, A. K. (1998). Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J. Biol. Chem. 273, 7382-7389.
19. Riley, R. J., and Workman, P. (1992). DT-diaphorase and cancer chemotherapy. Biochem. Pharmacol. 43, 1657-1669.
20. Rosenquist, T. A., Einolf, H. J., Dickman, K. G., Wang, L., Smith, A., and Grollman, A. P. (2010). Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug Metab. Dispos. 38, 761-768.
21. Ross, D., Siegel, D., Beall, H., Prakash, A. S., Mulcahy, R. T., and Gibson, N. W. (1993). DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C. Cancer Metastasis Rev. 12, 83-101.
22. Sato, N., Takahashi, D., Chen, S. M., Tsuchiya, R., Mukoyama, T., Yamagata, S., Ogawa, M., Yoshida, M., Kondo, S., Satoh, N., et al. (2004). Acute nephrotoxicity of aristolochic acids in mice. J. Pharm. Pharmacol. 56, 221-229.
23. Schlager, J. J., and Powis, G. (1990). Cytosolic NAD(P)H:(quinone-acceptor) oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int. J. Cancer. 45, 403-409.
24. Schmeiser, H. H., Pool, B. L., and Wiessler, M. (1986). Identification and mutagenicity of metabolites of aristolochic acid formed by rat liver. Carcinogenesis 7, 59-63.
25. Schmeiser, H. H., Schoepe, K. B., and Wiessler, M. (1988). DNA adduct formation of aristolochic acid I and II in vitro and in vivo. Carcinogenesis 9, 297-303.
26. Shibutani, S., Bonala, R. R., Rosenquist, T., Rieger, R., Suzuki, N., Johnson, F., Miller, F., and Grollman, A. P. (2010). Detoxification of aristolochic acid I by O-demethylation: less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents. Int. J. Cancer 127, 1021-1027.
27. Shibutani, S., Dong, H., Suzuki, N., Ueda, S., Miller, F., and Grollman, A. P. (2007). Selective toxicity of aristolochic acids I and II. Drug Metab. Dispos. 35, 1217-1222.
28. Sistkova, J., Hudecek, J., Hodek, P., Frei, E., Schmeiser, H. H., and Stiborova, M. (2008). Human cytochromes P450 1A1 and 1A2 participate in detoxication of carcinogenic aristolochic acid. Neuro. Endocrinol. Lett. 29, 733-737.
29. Stiborova, M., Frei, E., Arlt, V. M., and Schmeiser, H. H. (2008a). Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat. Res. 658, 55-67.
30. Stiborova, M., Frei, E., Breuer, A., Wiessler, M., and Schmeiser, H. H. (2001a). evidence for reductive activation of carcinogenic aristolochic acids by prostaglandin H synthase-(32)P-postlabeling analysis of DNA adduct formation. Mutat. Res. 493, 149-160.
31. Stiborova, M., Frei, E., Hodek, P., Wiessler, M., and Schmeiser, H. H. (2005). Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:-cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int. J. Cancer 113, 189-197.
32. Stiborova, M., Frei, E., and Schmeiser, H. H. (2008b). Biotransformation enzymes in development of renal injury and urothelial cancer caused by aristolochic acid. Kidney Int. 73, 1209-1211.
33. Stiborova, M., Frei, E., Sopko, B., Sopkova, K., Markova, V., Lankova, M., Kumstyrova, T., Wiessler, M., and Schmeiser, H. H. (2003). Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:-quinone oxidoreductase. Carcinogenesis 24, 1695-1703.
34. Stiborova, M., Frei, E., Sopko, B., Wiessler, M., and Schmeiser, H. H. (2002). Carcinogenicaristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis 23, 617-625.
35. Stiborova, M., Frei, E., Wiessler, M., and Schmeiser, H. H. (2001b). Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: Evidence for reductive activation by cytochromes P450 1A1 and 1A2. Chem. Res. Toxicol. 14, 1128-1137.
36. Stiborova, M., Hajek, M., Frei, E., and Schmeiser, H. H. (2001c). Carcinogenic and nephrotoxic alkaloids aristolochic acids upon activation by NADPH: cytochrome P450 reductase form adducts found in DNA of patients with Chinese herbs nephropathy. Gen. Physiol. Biophys. 20, 375-392.
37. Stiborova,M., Mareis, J., Frei, E., Arlt,V.M., Martinek, V., and Schmeiser, H. H. (2011). The human carcinogen aristolochic acid i is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases. Environ. Mol. Mutagen. doi:10.1002/em.20642. Advance Access published on March 2, 2011.
38. Xiao, Y., Ge, M., Xue, X., Wang, C., Wang, H., Wu, X., Li, L., Liu, L., Qi, X., Zhang, Y., et al. (2008). Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. Kidney Int. 73, 1231-1239.
39. Xiao, Y., Xue, X., Wu, Y. F., Xin, G. Z., Qian, Y., Xie, T. P., Gong, L. K., and Ren, J. (2009). beta-Naphthoflavone protects mice from aristolochic acid-Iinduced acute kidney injury in a CYP1A dependent mechanism. Acta Pharmacol. Sin 30, 1559-1565.
40. Xue, X., Xiao, Y., Zhu, H., Wang, H., Liu, Y., Xie, T., and Ren, J. (2008). Induction of P450 1A by 3-methylcholanthrene protects mice from aristolochic acid-I-induced acute renal injury. Nephrol. Dial. Transplant. 23, 3074-3081.